Influenza-associated costs | No influenza immunisation | Influenza immunisation | Costs avoided |
---|---|---|---|
Direct costs | |||
Laboratory diagnosis | 259,878,840 | 246,608,193 | 13,270,647 |
Medical consultations | 266,216,669 | 251,638,144 | 14,578,525 |
Drugs | 43,978,880 | 41,388,986 | 2,589,893 |
Hospitalisations | 1,866,950,845 | 1,773,439,651 | 93,511,195 |
Influenza immunisation to school-aged population | 27,421,602 | −27,421,602 | |
Total direct costs (third-party payer perspective) | 2,437,025,233 | 2,340,496,577 | 96,528,657 |
Indirect costs | |||
Productivity loss | 267,469,325 | 253,037,896 | 14,431,429 |
Premature death | 29,368,240 | 28,338,858 | 1,029,382 |
Total indirect costs | 296,837,565 | 281,376,755 | 15,460,811 |
Total costs of influenza (societal perspective) | 2,733,862,799 | 2,621,873,331 | 111,989,467 |